RBP-6300

Indivior Inc. · Phase 2 active Small molecule

At a glance

Generic name	RBP-6300
Also known as	buprenorphine hemiadipate HCl, naloxone HCl
Sponsor	Indivior Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Transfer of Subjects From Subutex/Suboxone to RBP-6300 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RBP-6300 CI brief — competitive landscape report
RBP-6300 updates RSS · CI watch RSS
Indivior Inc. portfolio CI